Slowing the progression of CHF: Drug therapy to correct neurohormonal abnormalities

Postgraduate Medicine

Volumn 109, Issue 3, 2001, Pages 36-45

  Ward, R Parker ^a   Anderson, Allen S ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISOPROLOL FUMARATE; BOSENTAN; CARVEDILOL; DIGOXIN; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FUMARIC ACID; LISINOPRIL; LOSARTAN; METOPROLOL; METOPROLOL TARTRATE; NESIRITIDE; NEUROHORMONE; OMAPATRILAT; SPIRONOLACTONE; VALSARTAN; VASOPEPTIDASE INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG INDICATION; DRUG MECHANISM; GENERAL PRACTITIONER; HEART EJECTION FRACTION; HEART FUNCTION; HEART VENTRICLE FUNCTION; HORMONE INHIBITION; HUMAN;

EID: 0035099806     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2001.03.874     Document Type: Conference Paper

References (21)

1. Heart failure: Recent advances in prevention and treatment
2. Hormones and hemodynamics in heart failure
3. Cost-effective management of heart failure
4. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
6. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
7. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. The SAVE Investigators
8. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE Inhibitor Trials
9. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
10. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
11. Effects of losartan vs captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - Elite II
12. The effect of the angiotension receptor blocker valsartan on morbidity and mortality in heart failure: The Valsartan Heart Failure Trial (Val-HeFT)
13. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: US Carvedilol Heart Failure Study Group
14. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
15. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
16. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
17. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
18. Endothelin antagonists
19. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial
20. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure
21. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure